Ractigen Therapeutics
Latest round
- Series A
Last raised
- Jan 2022
Total raised
- $48M
Investors
- 9
About Ractigen Therapeutics
, trading as Ractigen Therapeutics, develops RNA activation (RNAa)-based therapeutics and gene expression technologies for the treatment of genetic and other diseases. The company provides innovative gene medicines and disease treatments for many fields, such as tumors, liver targets, and the central nervous system. The company focuses on ribonucleic acid (RNA) activation technology. RNA technology can restart the expression of endogenous genes and restore proteins's natural function to treat disease. The company's product pipeline includes monogenetic disease products RAG-06, oncology products RAG-01, skin condition products RAG-11, and liver disease products RAG-03. The company develops the Smart-TTC and SCAD technology platforms. The company generates revenue by developing and commercializing RNA activation-based therapeutics, drug candidates, and related genetic medicine technologies.
Who invested in Ractigen Therapeutics
9 investors across 2 rounds
See all investors in Ractigen Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ractigen Therapeutics
Who invested in Ractigen Therapeutics?
Ractigen Therapeutics has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ractigen Therapeutics raised?
Ractigen Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Ractigen Therapeutics last raise money?
Ractigen Therapeutics's most recent round on record is a Series A, in Jan 2022.
What does Ractigen Therapeutics do?
, trading as Ractigen Therapeutics, develops RNA activation (RNAa)-based therapeutics and gene expression technologies for the treatment of genetic and other diseases.
Where is Ractigen Therapeutics headquartered?
Ractigen Therapeutics is headquartered in Nantong, China.
Which VCs invest in companies like Ractigen Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Ractigen Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Ractigen Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.